$0.395
-0.0249[-5.93%]
At close: Apr 17
$0.395
0[0.00%]
After Hours: 9:26AM EDT
NeuBase Therapeutics
(NASDAQ:NBSE)NeuBase Therapeutics Stock (NASDAQ:NBSE), Analyst Ratings, Price Targets, Predictions
NeuBase Therapeutics Inc has a consensus price target of $2.75, established from looking at the 7 latest analyst ratings. The last 3 analyst ratings were released from Oppenheimer, RBC Capital, and Chardan Capital on October 21, 2022, October 18, 2022, and October 17, 2022. With an average price target of $0.33 between Oppenheimer, RBC Capital, and Chardan Capital, there's an implied -15.61% downside for NeuBase Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Oppenheimer
RBC Capital
Chardan Capital
HC Wainwright & Co.
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for NeuBase Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10/21/2022 | NBSE | Buy Now | NeuBase Therapeutics | $0.40 | — | Oppenheimer | Hartaj Singh | — | Downgrade | Outperform → Perform | Get Alert |
| 10/18/2022 | NBSE | Buy Now | NeuBase Therapeutics | $0.40 | 153.16% | RBC Capital | Leonid Timashev | $240 → $20 | Downgrade | Outperform → Sector Perform | Get Alert |
| 10/17/2022 | NBSE | Buy Now | NeuBase Therapeutics | $0.40 | — | Chardan Capital | Keay Nakae | — | Downgrade | Buy → Neutral | Get Alert |
| 08/12/2022 | NBSE | Buy Now | NeuBase Therapeutics | $0.40 | 1672.15% | Chardan Capital | Keay Nakae | $180 → $140 | Maintains | Buy | Get Alert |
| 05/31/2022 | NBSE | Buy Now | NeuBase Therapeutics | $0.40 | 2431.65% | HC Wainwright & Co. | Raghuram Selvaraju | $300 → $200 | Maintains | Buy | Get Alert |
| 05/13/2022 | NBSE | Buy Now | NeuBase Therapeutics | $0.40 | 2178.48% | Chardan Capital | Keay Nakae | $360 → $180 | Maintains | Buy | Get Alert |
| 06/01/2021 | NBSE | Buy Now | NeuBase Therapeutics | $0.40 | 3697.47% | HC Wainwright & Co. | Raghuram Selvaraju | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for NeuBase Therapeutics (NBSE)?
The latest price target for NeuBase Therapeutics (NASDAQ: NBSE) was reported by Oppenheimer on October 21, 2022. The analyst firm set a price target for $0.00 expecting NBSE to fall to within 12 months (a possible -100.00% downside). 0 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for NeuBase Therapeutics (NBSE)?
The latest analyst rating for NeuBase Therapeutics (NASDAQ: NBSE) was provided by Oppenheimer, and NeuBase Therapeutics downgraded their perform rating.
When was the last upgrade for NeuBase Therapeutics (NBSE)?
There is no last upgrade for NeuBase Therapeutics.
When was the last downgrade for NeuBase Therapeutics (NBSE)?
The last downgrade for NeuBase Therapeutics Inc happened on October 21, 2022 when Oppenheimer changed their price target from N/A to N/A for NeuBase Therapeutics Inc.
When is the next analyst rating going to be posted or updated for NeuBase Therapeutics (NBSE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NeuBase Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NeuBase Therapeutics was filed on October 21, 2022 so you should expect the next rating to be made available sometime around October 21, 2023.
Is the Analyst Rating NeuBase Therapeutics (NBSE) correct?
While ratings are subjective and will change, the latest NeuBase Therapeutics (NBSE) rating was a downgraded with a price target of $0.00 to $0.00. The current price NeuBase Therapeutics (NBSE) is trading at is $0.40, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.